{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:52:05Z","timestamp":1793641925241,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40487-021-00167-z","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T02:02:43Z","timestamp":1628301763000},"page":"347-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions"],"prefix":"10.1007","volume":"9","author":[{"given":"Melek","family":"Akay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionut-Gabriel","family":"Funingana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grisma","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Mustapha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernese","family":"Gjafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-4075","authenticated-orcid":false,"given":"Kenrick","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"issue":"6835","key":"167_CR1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/35077232","volume":"411","author":"JH Hoeijmakers","year":"2001","unstructured":"Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366\u201374.","journal-title":"Nature"},{"issue":"6330","key":"167_CR2","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","journal-title":"Science"},{"issue":"8\u20139","key":"167_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.dnarep.2004.06.002","volume":"3","author":"A Huber","year":"2004","unstructured":"Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair (Amst). 2004;3(8\u20139):1103\u20138.","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"167_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","volume":"17","author":"TA Hopkins","year":"2019","unstructured":"Hopkins TA, Ainsworth WB, Ellis PA, et al. PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow. Mol Cancer Res. 2019;17(2):409\u201319.","journal-title":"Mol Cancer Res"},{"issue":"6160","key":"167_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1126\/science.1244669","volume":"342","author":"SM Nijman","year":"2013","unstructured":"Nijman SM, Friend SH. Potential of the synthetic lethality principle. Science. 2013;342(6160):809\u201311.","journal-title":"Science"},{"issue":"9","key":"167_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882\u201392.","journal-title":"Lancet Oncol"},{"issue":"22","key":"167_CR7","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1021\/jm901188v","volume":"52","author":"P Jones","year":"2009","unstructured":"Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009;52(22):7170\u201385.","journal-title":"J Med Chem"},{"issue":"8","key":"167_CR8","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1021\/jm5018237","volume":"58","author":"P Jones","year":"2015","unstructured":"Jones P, Wilcoxen K, Rowley M, Toniatti C. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination. J Med Chem. 2015;58(8):3302\u201314.","journal-title":"J Med Chem"},{"issue":"12","key":"167_CR9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1158\/1535-7163.TARG-15-B168","volume":"14","author":"KWK Mikule","year":"2015","unstructured":"Mikule KWK. Abstract B168: The PARP inhibitor niraparib crosses the blood brain barrier in rodents and is efficacious in a BRCA2 mutant intracranial tumor model. Mol Cancer Ther. 2015;14(12):168.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"167_CR10","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"2","key":"167_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","volume":"159","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Benigno B, D\u00f8rum A, et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16\/NOVA trial. Gynecol Oncol. 2020;159(2):442\u20138.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"167_CR12","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20(1):e15\u201328.","journal-title":"Lancet Oncol"},{"issue":"8","key":"167_CR13","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","volume":"29","author":"JS Berek","year":"2018","unstructured":"Berek JS, Matulonis UA, Peen U, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;29(8):1784\u201392.","journal-title":"Ann Oncol"},{"issue":"8","key":"167_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","volume":"19","author":"AM Oza","year":"2018","unstructured":"Oza AM, Matulonis UA, Malander S, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018;19(8):1117\u201325.","journal-title":"Lancet Oncol"},{"issue":"25","key":"167_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"5","key":"167_CR16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636\u201348.","journal-title":"Lancet Oncol"},{"issue":"15","key":"167_CR17","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22(15):3764\u201373.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"167_CR18","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606\u201322.","journal-title":"Ann Oncol"},{"issue":"26","key":"167_CR19","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"},{"issue":"26","key":"167_CR20","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"28","key":"167_CR21","doi-asserted-by":"publisher","first-page":"14174","DOI":"10.1073\/pnas.1821194116","volume":"116","author":"AL Elaimy","year":"2019","unstructured":"Elaimy AL, Amante JJ, Zhu LJ, et al. The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP\/TAZ-mediated Rad51 expression. Proc Natl Acad Sci U S A. 2019;116(28):14174\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"167_CR22","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"10","key":"167_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","volume":"20","author":"MR Mirza","year":"2019","unstructured":"Mirza MR, Avall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;20(10):1409\u201319.","journal-title":"Lancet Oncol"},{"key":"167_CR24","doi-asserted-by":"crossref","unstructured":"Hardesty MM KT, Wright GS et al. Phase 2 OVARIO study of niraparib plus bevacizumab therapy in advanced ovarian cancer following frontline platinum-base chemotherapy with bevacizumab. Society of Gynecologic Oncology Virtual Annual Meeting on Women\u2019s Cancer. 2021.","DOI":"10.1016\/S0090-8258(21)00679-X"},{"issue":"3","key":"167_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/diagnostics10030146","volume":"10","author":"F Borella","year":"2020","unstructured":"Borella F, Ghisoni E, Giannone G, et al. Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. Diagnostics (Basel). 2020;10(3):146.","journal-title":"Diagnostics (Basel)."},{"key":"167_CR26","doi-asserted-by":"crossref","unstructured":"Constantia Pantelidou HJ, Aditi Kothari, Renyan Liu, Jennifer L. Guerriero, Geoffrey I. Shapiro. STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer. bioRxiv. 2021.","DOI":"10.1101\/2021.01.26.428337"},{"key":"167_CR27","doi-asserted-by":"publisher","first-page":"110972","DOI":"10.1016\/j.biopha.2020.110972","volume":"133","author":"H Du","year":"2021","unstructured":"Du H, Xu T, Cui M. cGAS-STING signaling in cancer immunity and immunotherapy. Biomed Pharmacother. 2021;133:110972.","journal-title":"Biomed Pharmacother"},{"key":"167_CR28","doi-asserted-by":"publisher","first-page":"e60637","DOI":"10.7554\/eLife.60637","volume":"9","author":"C Kim","year":"2020","unstructured":"Kim C, Wang XD, Yu Y. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response. Elife. 2020;9:e60637.","journal-title":"Elife"},{"issue":"1","key":"167_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","volume":"19","author":"J Zheng","year":"2020","unstructured":"Zheng J, Mo J, Zhu T, et al. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19(1):133.","journal-title":"Mol Cancer"},{"issue":"1","key":"167_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. Cancer Discov. 2020;10(1):26\u201339.","journal-title":"Cancer Discov"},{"issue":"4","key":"167_CR31","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.4049\/jimmunol.1601694","volume":"198","author":"Y Kitai","year":"2017","unstructured":"Kitai Y, Kawasaki T, Sueyoshi T, et al. DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J Immunol. 2017;198(4):1649\u201359.","journal-title":"J Immunol"},{"issue":"7477","key":"167_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature12640","volume":"503","author":"A Ablasser","year":"2013","unstructured":"Ablasser A, Schmid-Burgk JL, Hemmerling I, et al. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature. 2013;503(7477):530\u20134.","journal-title":"Nature"},{"issue":"14","key":"167_CR33","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao S, Xia W, Yamaguchi H, et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017;23(14):3711\u201320.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"167_CR34","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang Z, Sun K, Xiao Y, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9(1):1853.","journal-title":"Sci Rep"},{"issue":"11","key":"167_CR35","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25(11):2972-2980 e2975.","journal-title":"Cell Rep"},{"issue":"6","key":"167_CR36","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria TM, et al. PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov. 2019;9(6):722\u201337.","journal-title":"Cancer Discov"},{"issue":"8","key":"167_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019;5(8):1141\u20139.","journal-title":"JAMA Oncol"},{"key":"167_CR38","doi-asserted-by":"crossref","unstructured":"Liu JF GS, Wahner Hendrickson AE, et al. An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of the OPAL trial. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women's Cancer. March 2021.","DOI":"10.1016\/S0090-8258(21)00680-6"},{"issue":"7","key":"167_CR39","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/bjc.2015.81","volume":"112","author":"M Koti","year":"2015","unstructured":"Koti M, Siu A, Cl\u00e9ment I, et al. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer. 2015;112(7):1215\u201322.","journal-title":"Br J Cancer"},{"issue":"3","key":"167_CR40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/path.4404","volume":"234","author":"H Xu","year":"2014","unstructured":"Xu H, Xian J, Vire E, et al. Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells. J Pathol. 2014;234(3):386\u201397.","journal-title":"J Pathol"},{"issue":"12","key":"167_CR41","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland KC, Howitt BE, Shukla SA, et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12):13587\u201398.","journal-title":"Oncotarget"},{"key":"167_CR42","doi-asserted-by":"crossref","unstructured":"Jeyasekharan AD. PARP inhibitors need an extra STING for therapeutic efficacy. Sci Transl Med. 2019;11(494).","DOI":"10.1126\/scitranslmed.aax9557"},{"key":"167_CR43","doi-asserted-by":"crossref","unstructured":"Bartoletti M, Pelizzari G, Gerratana L, et al. Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis. Int J Mol Sci. 2020;21(11).","DOI":"10.3390\/ijms21113805"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-021-00167-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-021-00167-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-021-00167-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T21:23:44Z","timestamp":1673040224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-021-00167-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["167"],"URL":"https:\/\/doi.org\/10.1007\/s40487-021-00167-z","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}